- Home
- APGE vs ATAT Comparison
APGE vs ATAT Comparison
Compare APGE & ATAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APGE
- ATAT
- Stock Information
- Founded
- APGE 2022
- ATAT 2013
- Country
- APGE United States
- ATAT China
- Employees
- APGE N/A
- ATAT N/A
- Industry
- APGE Biotechnology: Biological Products (No Diagnostic Substances)
- ATAT Hotels/Resorts
- Sector
- APGE Health Care
- ATAT Consumer Discretionary
- Exchange
- APGE Nasdaq
- ATAT Nasdaq
- Market Cap
- APGE 3.0B
- ATAT 3.5B
- IPO Year
- APGE 2023
- ATAT 2022
- Fundamental
- Price
- APGE $48.46
- ATAT $28.25
- Analyst Decision
- APGE Strong Buy
- ATAT Strong Buy
- Analyst Count
- APGE 6
- ATAT 2
- Target Price
- APGE $75.40
- ATAT $23.69
- AVG Volume (30 Days)
- APGE 588.6K
- ATAT 1.6M
- Earning Date
- APGE 11-12-2024
- ATAT 11-19-2024
- Dividend Yield
- APGE N/A
- ATAT 1.60%
- EPS Growth
- APGE N/A
- ATAT 162.91
- EPS
- APGE N/A
- ATAT 1.20
- Revenue
- APGE N/A
- ATAT $950,764,843.00
- Revenue This Year
- APGE N/A
- ATAT $55.06
- Revenue Next Year
- APGE N/A
- ATAT $25.11
- P/E Ratio
- APGE N/A
- ATAT $22.52
- Revenue Growth
- APGE N/A
- ATAT 76.11
- 52 Week Low
- APGE $22.20
- ATAT $15.22
- 52 Week High
- APGE $72.29
- ATAT $29.90
- Technical
- Relative Strength Index (RSI)
- APGE 47.85
- ATAT 60.35
- Support Level
- APGE $41.85
- ATAT $26.50
- Resistance Level
- APGE $48.27
- ATAT $28.66
- Average True Range (ATR)
- APGE 3.56
- ATAT 1.28
- MACD
- APGE 0.31
- ATAT 0.19
- Stochastic Oscillator
- APGE 47.51
- ATAT 76.71
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Its two programs are APG777 and APG808, which initially develop for treating AD and COPD, respectively.
About ATAT Atour Lifestyle Holdings Limited
Atour Lifestyle Holdings Ltd is an upper-midscale hotel chain in China. The company derives revenues from franchise and management fees from its manachised hotels and sales of hotel supplies to manachised hotels, Operations of leased hotels, and sales of retail products. The company has one operating segment, which is the Atour Group.